

Reviewer's code: 00503345

COMMENTS TO AUTHORS

In this manuscript the authors review the rapidly growing clinical information of the impact of new direct acting antivirals on hepatitis C virus clearance and infection eradication. The efficacy of these antiviral treatments on fibrosis and HCV- related liver diseases such as cirrhosis and increased risk hepatocellular carcinoma are discussed. The potential benefits in term of economic burden associated with patient's death and number liver transplantations due to organ failure are estimated.

General Comments: Overall the review is well written and almost comprehensive. Major points.

1. The three tables are not easy reading as presented. More compact tables would help. **Tables have been simplified**

2. A table listing all the direct acting antivirals cited in the review and their targets should be included.

Thank you for the comment, a Table listing all the direct acting antivirals has been added to the text

3. Although the potential impact of the new direct acting antivirals is well discussed, it is not clear whether these regimens will reduce the risk of resistance to anti-HCV therapies. To my knowledge resistances to new direct acting antivirals have been reported and this should be briefly discussed.

Thank you for the comment, a brief discussion about resistance to DAAs has been added.

Minor points. A list of abbreviations would be useful since some abbreviations are not defined immediately after the first use in the text. **Abbreviations have been spelled out.**

Reviewer's code: 00006518

COMMENTS TO AUTHORS

Comments:

1. Concerning the authorship in a review article (usually very small in numbers) and judged from 'author contributions' stated by the authors, please clarify the role of the rest authors other than Ponziani FR, Mangiola F, and Binda C. **The role of the other Authors has been clarified.**

2. Spell-check (such as 'reviewed literature' instead of 'reviexed literature' in 'Author Contribution' and lowercase for 'Countries' in 'Abstract', format for references, etc.) and grammar-check (for a better readability) needed. **The aforementioned issues have been resolved.**

3. Cautious citation for proper references suggested, e.g. reference 24 is a 'letter to editor' (for reference 25) instead of an 'original article', reference 36 has nothing to do with DAAs, reference 70 is a review paper but not an original article addressing the incidence of HCC being reduced by HCV viral clearance as the author mentioned paper (published in 1995), Veldt et al.'s article is reference 47 not 49, reference 56 is a review article which did not address specifically on molecular mechanisms on liver fibrosis after HCV being cleared by DAAs, etc. **We apologize for reference mistakes, we extensively revised all mentioned references.**

4. Take care of the reference style for WJG (to add PMID or not?). **References style has been corrected.**
5. The authors need to clarify more clearly for the final two sentences in 'IMPACT OF VIRAL ERADICATION ON LIVER FIBROSIS' (references 60-67 and 56) for better readability and understading. **The sentences have been clarified.**
6. Duplicate sentence "This finding is associated with...during antiviral treatment with DAAs." in 'IMPACT OF VIRAL ERADICATION ON THE DEVELOPMENT OF HCC'. **Duplicate sentence has been deleted.**
7. Correct abbreviation for simeprevir to 'SMV' under '2. DAAs treatment after liver transplantation' section. **Corrected**
8. Please reorganized 'CONCLUSION' to a better & concise form, and avoid too many 'nevertheless' in its current version. **Conclusion paragraph has been reorganized.**

Reviewer's code: 02462179

COMMENTS TO AUTHORS

In this study, the authors summarized the basic information of direct acting antivirals and the impact of HCV eradication on liver cirrhosis, fibrosis, hepatocellular carcinoma. They also described the associations of direct acting antivirals and liver transplantation. Finally, the future prospect of HCV infection and HCV-related complication was demonstrated in the end of the article. The topic was interesting. However, the basic information of direct acting antivirals should be summarized in tables or figures. They are more concise and easy to read. **Main information about DAAs has been summarized in a Table as suggested.**

Moreover, how about the drug resistance in the process of antiviral treatment? **Thank you for the comment, a brief discussion about resistance to DAAs has been added.**

Furthermore, professional are needed to correct the English of manuscript.

Reviewer's code: 03648382

COMMENTS TO AUTHORS

This review is summarized on the impact of HCV eradication and DAAs on HCV infection related liver disease. An overall evaluation was an extensive and good article. However the tables were not very clear. Tables should be simplified. **Tables have been simplified.**

In addition more emphasis should be made high costs and resistance about DAAs. **A brief discussion about resistance to DAAs has been added.** High costs of DAAs and their consequences have been briefly discussed in the final part of the manuscript but we think that an extensive revision of this topic is beyond the aim of this review.

Reviewer's code: 03020633

COMMENTS TO AUTHORS

This review is comprehensive on the impact of HCV eradication or SVR on HCV infection related liver disease, such as liver fibrosis, liver cirrhosis decompensation, HCC and liver transplantation. While, I think that the content of effect antiviral therapy by IFN+RBV treatment on liver disease was a little lengthy and should be compressed. **The paragraph has been shortened.**

The content about DAA on HCV related liver disease is well reviewed and very readable. **Thanks**

Due to the high cost, DAA may be only applicable in developed countries in the near future.

There is a long way to go to assess DAA on situations of HCV infection globally.